Raritan, NJ /PRNewswire/ - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the CE Mark availability of the semi-automated ORTHO Optix™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform.
The ORTHO Optix Reader's high-resolution camera captures color, grayscale, front and back images of each test without operator intervention, which provides objective data for automated results interpretation and eliminates the subjectivity and discrepancies of multiple operators reviewing images by eye.
When paired with the ORTHO™ Workstation, the ORTHO Optix Reader provides a complete semi-automated testing platform for transfusion labs with low- to mid-volume throughput. Because the ORTHO Optix Reader has been shown to deliver 99.9% concordance1 with the fully automated ORTHO VISION® Analyzer, it also offers larger volume labs and health care networks a way to back-up or scale up their operations without having to invest in an additional full-automation analyzer. The concordant and high-resolution images of the ORTHO Optix Reader also help to support the technologist during remote review of results from across the laboratory.
"The ORTHO Optix Reader allows transfusion medicine labs with smaller testing volumes the same high-quality, consistent results demonstrated from the award-winning, fully automated ORTHO VISION Analyzer," said Bob Stowers, Ortho's head of transfusion medicine product portfolio. "With the ORTHO Optix Reader now included in Ortho's comprehensive portfolio of automated and semi-automated solutions, labs of all sizes can customize Ortho's solutions to optimize their resources without compromising quality and accuracy."
The ORTHO Optix Reader leverages the same proven ORTHO BioVue® System Column Agglutination Technology as the ORTHO VISION Analyzer and a comprehensive testing menu including antibody panels, selected cells and dilution series.
When connected to the customer's LIS, column grades and images can be automatically sent for long-term retention of result interpretations, therefore reducing and/or eliminating the need for manual documentation of results. The system audit log and reporting module enhances traceability to help labs stay compliant with accreditations and regulations. It also includes QC management capabilities along with assay and reagent tracking to help standardize lab practices.
The ORTHO Optix Reader is supported by Ortho Care™, Ortho's award-winning, holistic service and support solution, and is now available in countries that accept CE Mark.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, serves the clinical laboratory and immunohematology communities.
Ortho's high-quality products and services help hospitals, hospital networks, blood banks and labs in more than 125 countries and territories deliver consistently fast, accurate and reliable results that allow clinicians to make better-informed treatment decisions.
Ortho's lab solutions provide sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories to help them run more efficiently and effectively and improve patient care.
Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit.
Why does Ortho continue to innovate and provide industry-changing solutions? Because every test is a life.
For more information about Ortho's solutions and services, visit www.orthoclinicaldiagnostics.com, or visit Ortho on social media: LinkedIn, Twitter, Facebook, Instagram and YouTube.
© Ortho Clinical Diagnostics 2020
1 For direct and indirect antiglobulin testing, as determined by External Validation Testing using BioVue® Technology. The acceptance criteria for concordance for direct and indirect antiglobulin was ≥98.0% with a lower bound 95% CI of 99.7%.